These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 37160689)

  • 1. Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: A multicenter randomized controlled trial in China.
    Hu J; Mei H; Su NY; Sun WJ; Zhang DK; Fan LL; He P; Pan J; Wang XW; Zou PY; Liu YX; Guo Y; Lan CH
    Helicobacter; 2023 Aug; 28(4):e12970. PubMed ID: 37160689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vonoprazan Dual or Triple Therapy Versus Bismuth-Quadruple Therapy as First-Line Therapy for Helicobacter pylori Infection: A Three-Arm, Randomized Clinical Trial.
    Cheung KS; Lyu T; Deng Z; Han S; Ni L; Wu J; Tan JT; Qin J; Ng HY; Leung WK; Seto WK
    Helicobacter; 2024; 29(5):e13133. PubMed ID: 39244723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ten-Day Vonoprazan-Amoxicillin Dual Therapy vs Standard 14-Day Bismuth-Based Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Multicenter Randomized Clinical Trial.
    Yan TL; Wang JH; He XJ; Zhu YB; Lu LJ; Wang YJ; Wang ZW; Gao JG; Xu CF; Ma H; Luan SM; Li L; Chen Y
    Am J Gastroenterol; 2024 Apr; 119(4):655-661. PubMed ID: 37975609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of vonoprazan-based dual therapy with vonoprazan-based bismuth quadruple therapy for treatment-naive patients with Helicobacter pylori infection: A propensity score matching analysis.
    Liu Z; Chen X; Sun DJ; Zhao WW; Kou L; Zheng WW; Hao JR; Gao FY
    Medicine (Baltimore); 2024 Mar; 103(10):e37476. PubMed ID: 38457567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy.
    Qian HS; Li WJ; Dang YN; Li LR; Xu XB; Yuan L; Zhang WF; Yang Z; Gao X; Zhang M; Li X; Zhang GX
    Am J Gastroenterol; 2023 Apr; 118(4):627-634. PubMed ID: 36729890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
    Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
    Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose amoxicillin-proton pump inhibitor dual therapy as first-line treatment for Helicobacter pylori infection in Northwest China: A prospective, randomised controlled trial.
    Yun JW; Wang C; Yu Y; Xu HM; Gou LZ; Li XL; Yi GR; Lin YM; Han TY; Zhang DK
    Br J Clin Pharmacol; 2023 Jan; 89(1):232-241. PubMed ID: 35947524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study.
    Han YY; Zhou L; Hu YL; Ding XW; Long H; Liu F; Xu M; Zhang ZY; Li SL; Wang QY; Su CX; Chen Y; Chen J; Lin Y; Li PY
    J Gastroenterol; 2023 Dec; 58(12):1167-1177. PubMed ID: 37777987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
    Chen S; Shen W; Liu Y; Dong Q; Shi Y
    Chin Med J (Engl); 2023 Jul; 136(14):1690-1698. PubMed ID: 37469024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial.
    Bi H; Chen X; Chen Y; Zhao X; Wang S; Wang J; Lyu T; Han S; Lin T; Li M; Yuan D; Liu J; Shi Y
    Chin Med J (Engl); 2022 Jul; 135(14):1707-1715. PubMed ID: 36193978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
    Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
    Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of vonoprazan and amoxicillin as the first-line Helicobacter pylori eradication therapy: a multicenter, prospective, randomized, parallel-controlled study.
    Peng X; Chen HW; Wan Y; Su PZ; Yu J; Liu JJ; Lu Y; Zhang M; Yao JY; Zhi M
    Clin Exp Med; 2023 Nov; 23(7):4011-4019. PubMed ID: 37115412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vonoprazan and amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection: A systematic review and meta-analysis.
    Du RC; Hu YX; Ouyang Y; Ling LX; Xu JY; Sa R; Liu XS; Hong JB; Zhu Y; Lu NH; Hu Y
    Helicobacter; 2024; 29(1):e13039. PubMed ID: 38036941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vonoprazan and amoxicillin dual therapy for 14 days as the first-line treatment of Helicobacter pylori infection: A non-inferiority, randomized clinical trial.
    Hu Y; Huang XH; Zhou B; Liu ML; Liu YF; Yu T; Sun P; Tan BB; Hu Y; Cheng F; Pan XL; Hong JB; Shu X; Zhu Y; Lu NH
    Helicobacter; 2024; 29(1):e13045. PubMed ID: 39191423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial.
    Lu L; Wang Y; Ye J; Han Y; Lou G; Li Y; Yan H; Du Q
    Helicobacter; 2023 Feb; 28(1):e12940. PubMed ID: 36458325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing high-dose dual therapy with bismuth-containing quadruple therapy for the initial eradication of Helicobacter pylori infection on Hainan Island: A randomized, multicenter clinical trial.
    Liu DN; Wang QY; Li PY; Wu DH; Pan J; Chen ZY; Li YQ; Han XY; Lan C; Tang J; Tan Y; Mo CY; Yang WZ; Han JL; Huang XX
    Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102125. PubMed ID: 37062356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial.
    Song Z; Zhou L; Xue Y; Suo B; Tian X; Niu Z
    Helicobacter; 2020 Dec; 25(6):e12762. PubMed ID: 33040439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: An open-label, multicenter, randomized controlled trial.
    Guan JL; Hu YL; An P; He Q; Long H; Zhou L; Chen ZF; Xiong JG; Wu SS; Ding XW; Luo HS; Li PY
    Pharmacotherapy; 2022 Mar; 42(3):224-232. PubMed ID: 35075679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.
    Xie Y; Zhu Z; Wang J; Zhang L; Zhang Z; Lu H; Zeng Z; Chen S; Liu D; Lv N;
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vonoprazan-amoxicillin dual therapy for
    Zhou BG; Mei YZ; Jiang X; Zheng AJ; Ding YB
    Saudi J Gastroenterol; 2023; 29(6):347-357. PubMed ID: 37602635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.